APM
Aptorum Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$8.26
−14.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 960.8K | — | — | 431.4K | 1.3M |
| Cost of Revenue | — | — | 256.0K | 420.4K | 1.2M |
| Gross Profit | 960.8K | — | (256.0K) | 11.0K | 80.1K |
| Operating Expenses | |||||
| R&D Expense | 3.6M | 352.9K | 1.9M | 5.2M | 9.2M |
| SG&A Expense | 5.0M | 1.6M | 1.5M | 4.4M | 8.0M |
| General & Admin Expense | 974.7K | 1.6M | — | 4.4M | 7.9M |
| Selling & Marketing Expense | — | — | — | 49.0K | 98.1K |
| Other Expenses | (8.7K) | (170.8K) | 128.0K | 999.0K | 69.0K |
| Total Operating Expenses | 8.5M | 1.8M | 3.5M | 10.6M | 17.3M |
| Cost and Expenses | 9.5M | 1.8M | 3.8M | 11.0M | 18.8M |
| Operating Income (EBIT) | (6.3M) | (1.8M) | (3.8M) | (10.6M) | (17.5M) |
| Non-Operating | |||||
| Interest Income | 33.1K | — | — | — | 146.6K |
| Interest Expense | 21.7K | 95.7K | 146.9K | 121.1K | — |
| Net Interest Income | (72.3K) | (95.7K) | (146.9K) | (121.1K) | 146.6K |
| Other Non-Op Income/Expense | 23.4K | 441.1K | (361.0K) | 6.3M | 6.0M |
| Non-Operating Income (excl Interest) | 278.1K | — | 214.3K | — | (6.0M) |
| EBT (Pre-Tax Income) | (8.1M) | (1.4M) | (4.2M) | (4.3M) | (11.5M) |
| Income Tax Expense | 52.0K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (6.4M) | (1.4M) | (4.3M) | (2.8M) | (9.8M) |
| Earnings from Cont. Ops | (6.9M) | (1.4M) | (4.2M) | (4.3M) | (11.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.1M) | (1.4M) | (4.3M) | (2.8M) | (9.8M) |
| Per Share | |||||
| Basic EPS | ($5.12) | ($1.90) | ($7.80) | ($6.20) | ($27.50) |
| Diluted EPS | ($5.12) | ($1.90) | ($7.80) | ($6.20) | ($27.50) |
| Revenue Per Share | $1.18 | $0.00 | $0.00 | $0.95 | $3.63 |
| Shares | |||||
| Basic Shares Outstanding | 814375 | 735178 | 545300 | 452100 | 356900 |
| Diluted Shares Outstanding | 814375 | 735178 | 545300 | 452100 | 356900 |
| Profitability Metrics | |||||
| EBITDA | (6.6M) | (1.8M) | (3.8M) | (9.5M) | (10.3M) |
| D&A | — | — | 255.0K | 1.1M | 1.2M |
| EBIT | (8.0M) | (1.8M) | (4.0M) | (10.6M) | (11.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026